Kamran Miah

The development of SIV-based lentiviral vectors pseudotyped with Sendai virus F and HN proteins by the Gene Medicine Group has led to a promising gene therapy to treat Cystic Fibrosis (CF) lung disease. My role as a Postdoctoral Research Scientist is to support the development of our lentiviral vector technology for production of cGMP-compliant vectors. My work also concerns the development of relevant assays and protocols that will support the technology transfer and the further characterisation of the manufactured viral vector product. These efforts are focused on preparation for the first-in-human clinical trial of lentiviral vector gene therapy for CF.

Previously, I was based at the National Institute of Biological Standards and Control, undertaking my PhD research in affiliation with the University of Reading. My PhD research focused on using CRISPR/Cas9 to target human YB1 and insect homologues with the intention to improve recombinant AAV vector processing and production. Prior to this I completed my MSc studies in Infection and Immunity at Universtiy College London, and BSc Hons in Biomedical Sciences at Brunel University.